acetyl l carnitine and myasthenia gravis Gravis: Autoantibody Specificities Their Role in MG Management Acetyl-L-Carnitine | Douglas Labs

Administered as an oral rapid dissolve tablet (RDT)

Sigma E2011), docosapentaenoic acid (DPA, 25 M, Sigma D1797) ferrostatin-1 (fer-1, 0.011 M, Sigma, SML0583), -tocopherol (-toco, 0.11 M, Sigma, T3251), Z-VAD-FMK (0.1100 M, BD Bioscience, 550337), TNF (50 ng/ml, PeproTech), IFN (50 ng/ml, R&D), IL-1 (10 ng/ml, PeproTech), LPS (100 ng/ml, Sigma L4524), IFN (2500U/ml, PBL, 12401-1), IL-4 (10 ng/ml, PeproTech 214-14), IL-6 (20 ng/ml, PeproTech 216-16), IL-22 (10 ng/ml, PeproTech 210-22), cholic acid (1 M, Sigma C9282), deoxycholic acid (1 M, Sigma D2510), ursodeoxycholic acid (1 M, Sigma U5127),(+/)8(9)- and (+/)11(12)- and (+/)14(15)-EETs (0.25 M Cayman Chemicals, 50511, 50651, 50351), ML351 (10 M, Sigma, SML1353), PD146176 (0.5 M, Sigma, P4620), zileuton (10 M, Sigma, Z4277), NCTT-956 (2 M, Sigma, SML0499), piroxicam (20 M, Sigma, P5654), 5-HETE (200nM-1M, Cayman Chemicals, 34210), 15-HPETE (200nM-1M, Cayman Chemicals, 44720), PGE2 (50 ng/ml, Sigma, P0409), BAY117082 (10 M, Sigma, B5556), MG132 (125 nM, ApexBio, A2585)

Because baseline stabilization must be taken consistently and long term, tolerability is critical

10.1016/j.redox.2022.102293 76 MinchenkoO.KulishY